# Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

> **NCT06607757** · PHASE2 · RECRUITING · sponsor: **GBG Forschungs GmbH** · enrollment: 120 (estimated)

## Conditions studied

- CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

## Interventions

- **DRUG:** Capivasertib
- **DRUG:** Fulvestrant injection

## Key facts

- **NCT ID:** NCT06607757
- **Lead sponsor:** GBG Forschungs GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-04
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-08-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06607757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06607757, "Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06607757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*